Presentation is loading. Please wait.

Presentation is loading. Please wait.

L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X

Similar presentations


Presentation on theme: "L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X"— Presentation transcript:

1 Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009–2013 
L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X. Wang, Z. Jia  Clinical Microbiology and Infection  Volume 24, Issue 4, Pages (April 2018) DOI: /j.cmi Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2 Fig. 1 Inclusion of MDR-TB patients in analysis. MDR-TB, multidrug-resistant tuberculosis. Clinical Microbiology and Infection  , DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3 Fig. 2 Drug resistance among 159 MDR-TB patients whose second-line drug-susceptibility testing results were available. E, ethambutol; H, isoniazid; Km, kanamycin; MDR, multidrug resistance; MDR-FL, TB with resistance to isoniazid and rifampin, but not any second-line drugs; MDR-TB, multidrug-resistant tuberculosis; Ofx, ofloxacin; pre-XDR-TB, TB with resistance to isoniazid, rifampin and either ofloxacin or kanamycin; R, rifampicin; S, streptomycin; TB, tuberculosis; XDR, extensively drug resistant (TB with resistance to isoniazid, rifampin, and both ofloxacin and kanamycin). Clinical Microbiology and Infection  , DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

4 Fig. 3 Time to poor treatment outcome of MDR-TB by drug resistance pattern. Poor treatment outcome was defined as treatment failure, death or death. Log-rank test p value for trend of survivor functions =  MDR, multidrug resistant; MDR-FL, TB with resistance to isoniazid and rifampin, but not any second-line drugs; pre-XDR-TB, TB with resistance to isoniazid, rifampin and either ofloxacin or kanamycin; TB, tuberculosis; XDR, extensively drug resistant (TB with resistance to isoniazid, rifampin, and both ofloxacin and kanamycin). Clinical Microbiology and Infection  , DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions


Download ppt "L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X"

Similar presentations


Ads by Google